Off-label prescribing among office-based physicians

Radley, David C., Finkelstein, Stan N., Stafford, Randall S.·2006·Archives of Internal Medicine
DOI 10.1001/archinte.166.9.1021

Cited by (710)

Items 101–200 of 710

  1. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012
    Andreas Vilhelmsson, Courtney Davis, Shai Mulinari · 2016 · PLoS Medicine
  2. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.
    Rachel Vickers‐Smith, Elaine M. Boland, April M. Young, Michelle R. Lofwall, Alexa Quiroz, Michele Staton, Jennifer R. Havens · 2017 · Psychology of Addictive Behaviors
  3. Adherence to diagnostic guidelines and quality indicators in asthma and COPD in Swedish primary care
    Paolina Weidinger, J. Lars G. Nilsson, Ulf Lindblad · 2009 · Pharmacoepidemiology and Drug Safety
  4. Off-Label Use of Oncology Drugs: The Need for More Data and Then Some
    David G. Pfister · 2012 · Journal of Clinical Oncology
  5. Gabapentin—Friend or foe?
    Marc A. Russo, Brett Anthony Graham, Danielle M. Santarelli · 2022 · Pain Practice
  6. Bioethics and the Future of Stem Cell Research
    I. Hyun · 2013 · Cambridge University Press eBooks
  7. The Law and Practice of Off-Label Prescribing and Physician Promotion.
    Shariful A. Syed, Brigham A Dixson, Eduardo A. Constantino, Judith J Regan · 2021 · PubMed
  8. Neutropenia Associated with Long-Term Ceftaroline Use
    Katherine W. LaVie, Scott W. Anderson, Hollis R. O’Neal, Todd W. Rice, Tatiana C. Saavedra, Catherine S. O’Neal · 2015 · Antimicrobial Agents and Chemotherapy
  9. Off-Label Use of Sodium Valproate for Schizophrenia
    Einav Horowitz, Lisa Carroll Bergman, Charna Ashkenazy, Irit Moscona-Hurvitz, Haya Fogel‐Grinvald, Racheli Magnezi · 2014 · PLoS ONE
  10. Complementary or competing climates? Examining the interactive effect of service and ethical climates on company-level financial performance.
    Adam T. Myer, Christian Noble Thoroughgood, Susan Mohammed · 2016 · Journal of Applied Psychology
  11. IMI – Industry Guidelines and Ethical Considerations for Myopia Control Report
    Lyndon Jones, Björn Drobe, Jose Manuel González‐Méijome, Lyle S. Gray, Timo Kratzer, Steve Newman, Jason J. Nichols, Arne Ohlendorf, Stephanie Ramdass, Jacinto Santodomingo‐Rubido et al. · 2019 · Investigative Ophthalmology & Visual Science
  12. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
    Loreto Carmona, M.Á. Descalzo, D. Ruiz-Montesinos, Francisco Javier Manero Ruíz, Eva María Pérez-Pampín, Juan Jesús Gómez-Reino, on behalf of the BIOBADASER 2.0 Study Group · 2010 · Lara D. Veeken
  13. Patient Data: Property, Privacy & the Public Interest
    Marc A. Rodwin · 2010 · American Journal of Law & Medicine
  14. Use of medication for challenging behaviour in people with intellectual disability
    Gyles R. Glover, Sarah H. Bernard, David M. L. Branford, Anthony John Holland, André Strydom · 2014 · The British Journal of Psychiatry
  15. Unintended Consequences of Evidence-Based Treatment Policy Reform: Is Implementation the Goal or the Strategy for Higher Quality Care?
    Alayna L. Park, Katherine H. Tsai, Karen Guan, Bruce F. Chorpita · 2018 · Administration and Policy in Mental Health and Mental Health Services Research
  16. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital
    Masnoon Saiyed, Tarachand Lalwani, Devang Ashwinkumar Rana · 2015 · International Journal of Risk & Safety in Medicine
  17. Monitoring the Safety of Medicines Used Off-Label
    Gerald J. Dal Pan · 2012 · Clinical Pharmacology & Therapeutics
  18. Off‐label antidepressant use in children and adolescents compared with young adults: extent and level of evidence
    Angela S. Czaja, Robert J. Valuck · 2012 · Pharmacoepidemiology and Drug Safety
  19. Off-Label Prescribing in Older Patients
    Stephen H. Jackson, Paul A. F. Jansen, Arduino Aleksander Mangoni · 2012 · Drugs & Aging
  20. Challenges and Priorities for Research
    Brian W. McCrindle, Jennifer S. Li, Cedric Manlhiot, James S. Tweddell, Therese M. Giglia, Mary Patricia Massicotte, Paul Monagle, Rajesh Krishnamurthy, Kenneth W. Mahaffey, Alan D. Michelson et al. · 2014 · Circulation
  21. Hyposalivation and Xerostomia and Burning Mouth Syndrome
    Jaykrishna Thakkar, Christopher J. Lane · 2021 · Oral and Maxillofacial Surgery Clinics of North America
  22. Pharmaceutical Promotion to Physicians and First Amendment Rights
    Aaron Seth Kesselheim, Jerry Avorn · 2008 · New England Journal of Medicine
  23. Methylphenidate off-label use and safety
    Thierry C Trenque, Emmanuelle Herlem, Malak Abou Taam, Moustapha Dramé · 2014 · SpringerPlus
  24. Reasons for and frequency of off - label drug use
    Svetlana Goločorbin-Kon, Ivana M. Iličković, Momir Mikov · 2015 · Medicinski pregled
  25. Mandatory Disclaimers On Dietary Supplements Do Not Reliably Communicate The Intended Issues
    Aaron Seth Kesselheim, John Connolly, James R. Rogers, Jerry Avorn · 2015 · Health Affairs
  26. Drug use beyond the licence in palliative care: A systematic review and narrative synthesis
    Vera Hagemann, Claudia Bausewein, Constanze Rémi · 2019 · Palliative Medicine
  27. Off-label and unlicensed utilisation of medicines in a French paediatric hospital
    Perrine Joret-Descout, Sonia Prot‐Labarthe, Françoise Brion, Julie Bataille, J.-F. Hartmann, Olivier Bourdon · 2015 · International Journal of Clinical Pharmacy
  28. An analysis of the high psychotropic off-label use in psychiatric disorders
    Kavi K. Devulapalli, Henry A. Nasrallah · 2009 · Asian Journal of Psychiatry
  29. Off-label drug use in Psychiatry Outpatient Department: A prospective study at a Tertiary Care Teaching Hospital
    Devang Ashwinkumar Rana, Varsha Jitendra Patel, Darshan Kharadi, Kamlesh Patel · 2015 · Journal of Basic and Clinical Pharmacy
  30. Off-label use of antipsychotics: are we mad?
    Camilla Haw, Jean H. Stubbs · 2007 · Expert Opinion on Drug Safety
  31. What influences healthcare providers’ prescribing decisions? Results from a national survey
    Simani M. Price, Amie C. O’Donoghue, Lou Rizzo, Saloni Sapru, Kathryn J. Aikin · 2021 · Research in Social and Administrative Pharmacy
  32. A framework for Military Bioethics
    Maxwell J. Mehlman, Stephanie O. Corley · 2014 · Journal of Military Ethics
  33. Myoclonus in renal failure: Two cases of gabapentin toxicity
    Kenneth R. Kaufman, Amay Parikh, Lili Chan, Mary Barna Bridgeman, Milisha Shah · 2014 · Epilepsy & Behavior Case Reports
  34. Supporting medication discontinuation: provider preferences for interventions to facilitate deprescribing
    Amy M. Linsky, Mark M. Meterko, Kelly L. Stolzmann, Steven R. Simon · 2017 · BMC Health Services Research
  35. When All Else Fails
    Peter B. Rosenquist, Nagy A. Youssef, Sandarsh Surya, William Vaughn McCall · 2018 · Psychiatric Clinics of North America
  36. Detection of Adverse Drug Events and Other Treatment Outcomes Using an Electronic Prescribing System
    Tewodros Eguale, Robyn M Tamblyn, Nancy E. Winslade, David Llewellyn Buckeridge · 2008 · Drug Safety
  37. State-level response to gabapentin misuse in the United States: Implications and future direction
    Zoe A. Karavolis, Andrew B Su, Alyssa M. Peckham · 2021 · American Journal of Health-System Pharmacy
  38. Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
    Jeff Unger · 2013 · Current Diabetes Reports
  39. Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005
    Rena M. Conti, Alisa B. Busch, David Cutler · 2011 · Psychiatric Services
  40. Use of antiepileptic drugs and risk of falls in old age: A systematic review
    Ylva Haasum, Kristina Johnell · 2017 · Epilepsy Research
  41. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
    Baptiste Pignon, Chloé Tezenas du Montcel, Louise Carton, Antoine Pélissolo · 2017 · Current Psychiatry Reports
  42. Indications of atypical antipsychotics in the elderly
    Andrew McKean, Erik Monasterio · 2014 · Expert Review of Clinical Pharmacology
  43. The Rise and Fall of Gabapentin for Bipolar Disorder
    Catherine Anne Fullerton, Alisa B. Busch, Richard G. Frank · 2010 · Medical Care
  44. Ethics codes and use of new and innovative drugs
    Jan Borysowski, Hans‐Jörg Ehni, Andrzej Górski · 2018 · British Journal of Clinical Pharmacology
  45. From off-label prescribing towards a new FDA
    Alexander T. Tabarrok · 2008 · Medical Hypotheses
  46. Sexual Medicine, Sexual Bodies and the ‘Pharmaceutical Imagination’
    Barbara Marshall · 2009 · Science as Culture
  47. Extensions of indication throughout the drug product lifecycle: a quantitative analysis
    Joris Langedijk, Christopher J. Whitehead, Diederick S. Slijkerman, Hubert G. M. Leufkens, Marie-Hélène D.B. Schutjens, Aukje Kaija Mantel-Teeuwisse · 2015 · Drug Discovery Today
  48. Physicians certified by the American Board of Obesity Medicine provide evidence‐based care
    Kimberly Anne Gudzune, Edmond P. Wickham, Stacy L. Schmidt, Fatima Cody Stanford · 2020 · Clinical Obesity
  49. Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States
    Michal Smogur, Alice Onesanu, Kerstin Jessica Plessen, Chin B. Eap, Nicolas Ansermot · 2022 · Journal of Child and Adolescent Psychopharmacology
  50. An outpatient antibacterial stewardship intervention during the journey to JCI accreditation
    Ping Song, Wei Li, Quan Zhou · 2014 · BMC Pharmacology and Toxicology
  51. Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy
    Valentina Franco, Maria Paola Canevini, Giuseppe Capovilla, Giovambattista De Sarro, Carlo Andrea Galimberti, Giuliana Gatti, Renzo Guerrini, Angela La Neve, Eleonora Rosati, Luigi Maria Specchio et al. · 2014 · CNS Drugs
  52. Frequency of the off-label use of antibiotics in clinical practice: a systematic review
    Giannoula S. Tansarli, Petros I. Rafailidis, Anastasios M. Kapaskelis, Matthew E. Falagas · 2012 · Expert Review of Anti-infective Therapy
  53. Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety
    Martina Bonifazi, Marta Rossi, Lorenzo Moja, Vincenzo Davide Scigliano, Matteo Franchi, Carlo La Vecchia, Carlo Zocchetti, Eva Negri · 2011 · The Oncologist
  54. Outcomes of off-label drug uses in hospitals: a multicentric prospective study
    Imma Danés, Antònia Agustí, Antonio Vallano, Carmen Alerany, J. Martínez, J. Bosch, A. Ferrer, Laura Gratacós Santanach, Alex Perez, M. Olmo et al. · 2014 · European Journal of Clinical Pharmacology
  55. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
    Markus Joerger, C. Schaer-Thuer, Dieter Koeberle, Klazien W Matter-Walstra, J. Gibbons Marsico, Stefan Diem, Beat Thuerlimann, Thomas Cerny · 2014 · European Journal of Clinical Pharmacology
  56. A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada from 2006 to 2012
    Rachael Morkem, David Barber, Tyler S. Williamson, Scott Burton Patten · 2015 · The Canadian Journal of Psychiatry
  57. Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012
    Julia Driessen, Seo Hyon Baik, Yuting Zhang · 2016 · Psychiatric Services
  58. Paediatric oral formulations: Why don't our kids have the medicines they need?
    José Eduardo Juárez‐Hernández, Bruce Carleton · 2022 · British Journal of Clinical Pharmacology
  59. Colon cancer patient information seeking and the adoption of targeted therapy for on‐label and off‐label indications
    Stacy W. Gray, Katrina Armstrong, Angela M. DeMichele, Jerome Sanford Schwartz, Robert Hornik · 2009 · Cancer
  60. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation
    Nancy M. Allen LaPointe, Laura A. Governale, Jerry Watkins, Jyotsna Mulgund, Kevin Joseph Anstrom · 2007 · American Heart Journal
  61. Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data
    Anne A. Eaton, Camelia S. Sima, Katherine S. Panageas · 2016 · Journal of the National Comprehensive Cancer Network
  62. Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study
    Ushma D. Upadhyay, Nicole E. Johns, Sarah Combellick, Julia E. Kohn, Lisa M. Keder, Sarah C. M. Roberts · 2016 · PLoS Medicine
  63. Japanese Regulatory System for Approval of Off-Label Drug Use: Evaluation of Safety and Effectiveness in Literature-Based Applications
    Shimazawa, Rumiko, Ikeda, Masayuki · 2012 · Clinical Therapeutics
  64. Ethical Transparency and Economic Medicalization
    Geoffrey Poitras, Lindsay N. Meredith · 2008 · Journal of Business Ethics
  65. A Hemorrhage of Off-Label Use
    Jerry Avorn, Aaron Seth Kesselheim · 2011 · Annals of Internal Medicine
  66. Indication creep: physician beware
    Paul C. Hébert, Matthew B. Stanbrook · 2007 · Canadian Medical Association Journal
  67. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France
    Marine Auffret, Julien Labreuche, Alain Duhamel, Sylvie Deheul, Olivier Cottencin, Régis Bordet, Sophie Gautier, Benjamin Rolland · 2016 · Drug Safety
  68. Dapoxetine for premature ejaculation
    Chris G. McMahon · 2010 · Expert Opinion on Pharmacotherapy
  69. Risk of Ischemic Cerebrovascular and Coronary Events in Adult Users of Anticonvulsant Medications in Routine Care Settings
    Elisabetta Patorno, Robert J. Glynn, Sonia Hernández–Dı́az, Jerry Avorn, Peter M. Wahl, Rhonda L. Bohn, Daniel I. Mines, Jun Liu, Sebastian Schneeweiß · 2013 · Journal of the American Heart Association
  70. Towards evidence‐based pharmacotherapy in children
    Elles Marleen Kemper, Maruschka P. Merkus, Peter C. Wierenga, Petra C. Van Rijn, D.B.M. van der Werff, Loraine Lie‐A‐Huen, Martin Offringa · 2010 · Pediatric Anesthesia
  71. Predictors of Polypharmacy and Off-Label Prescribing of Psychotropic Medications
    Marcia A. Kearns, Kristin M. Hawley · 2014 · Journal of Psychiatric Practice
  72. Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
    Bryan A. Liang, Tim Ken Mackey · 2010 · Science
  73. Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital
    Jennifer Corny, Benoît Bailey, Denis Lebel, Jean‐François Bussières · 2016 · Paediatrics & Child Health
  74. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice
    Amy Du, Cynthia M. Westerhout, Finlay Aleck McAlister, Miriam Shanks, Gavin Y. Oudit, D. Ian Paterson, Mikael Hanninen, Jissy Thomas, Justin Adrian Ezekowitz · 2018 · Journal of Cardiovascular Pharmacology
  75. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
    Meera M. Dhodapkar, Audrey D. Zhang, Jeremy Puthumana, Nicholas S. Downing, Nilay D. Shah, Joseph S. Ross · 2021 · JAMA Network Open
  76. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand.
    Erik Monasterio, Andrew McKean · 2011 · PubMed
  77. Regulating off-label drug use in India: The arena for concern
    Sukhvinder Singh Oberoi · 2015 · Perspectives in Clinical Research
  78. Off-label prescribing in a French hospital
    Audrey Cras, Marie-Agnès Conscience, Gérald Rajzbaum, Agnés Lillo‐Le Louët, Nathalie Lopez, Isabelle Tersen, Yvonnick Bézie · 2006 · Pharmacy World & Science
  79. Off-Label Use of Gastrointestinal Medications in the Intensive Care Unit
    Jeffrey F. Barletta, Ishaq Lat, Scott T. Micek, Henry Cohen, Keith M. Olsen, Curtis E. Haas, Critical Care Pharmacotherapy Trials Network · 2013 · Journal of Intensive Care Medicine
  80. Prevalence of Off-Label Use of Oral Oncolytics at a Community Cancer Center
    Joseph A Kalis, Simon J. Pence, Robert Mancini, Dan Sayam Zuckerman, Joseph R. Ineck · 2015 · Journal of Oncology Practice
  81. Medication-indication knowledge bases: a systematic review and critical appraisal
    Hojjat Salmasian, Tran H. Tran, Herbert S Chase, Carol Friedman · 2015 · Journal of the American Medical Informatics Association
  82. Quantitative EEG Neurometric Analysis–Guided Neurofeedback Treatment in Postconcussion Syndrome (PCS): Forty Cases. How Is Neurometric Analysis Important for the Treatment of PCS and as a Biomarker?
    Tanju Sürmeli, Emin Eralp, Ilham Mustafazade, Ismet H. Kos, Gül Elif Özer, Orkun H. Surmeli · 2016 · Clinical EEG and Neuroscience
  83. FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
    Bruce M. Psaty · 2008 · JAMA
  84. The End of the Risk–Treatment Paradox?
    Finlay Aleck McAlister · 2011 · Journal of the American College of Cardiology
  85. Brain Branding: When Neuroscience and Commerce Collide
    Bree Chancellor, Anjan Kumar Chatterjee · 2011 · AJOB Neuroscience
  86. The “Temporary Recommendations for Use”: A dual-purpose regulatory framework for off-label drug use in France
    Albane Degrassat-Théas, François Bocquet, M. Sinègre, Jérôme Peigné, Pascal Paubel · 2015 · Health Policy
  87. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer)
    Karim Tifratène, Franck Le Duff, Christian Pradier, Julien Quetel, Pierre Lafay, Stéphane Schück, Éric Benzenine, Catherine Quantin, Philippe Henri Robert · 2012 · Pharmacoepidemiology and Drug Safety
  88. Off-Label Use of Drugs and Medical Devices: A Review of Policy Implications
    Randall Scott Stafford · 2012 · Clinical Pharmacology & Therapeutics
  89. Efficacy of Dapoxetine in the Treatment of Premature Ejaculation
    Chris G. McMahon · 2011 · Clinical Medicine Insights Reproductive Health
  90. Prevalence and Perioperative Outcomes of Off-Label Total Hip and Knee Arthroplasty in the United States, 2000–2010
    Tennison L. Malcolm, Caleb R. Szubski, Nicholas K. Schiltz, Alison K. Klika, Siran M. Koroukian, Wael K. Barsoum · 2015 · The Journal of Arthroplasty
  91. Call for Action: Benzodiazepine Prescription Prevalence Analysis Shows Off-Label Prescription in One in Eleven Citizens
    Hugo López‐Pelayo, Anna Valeta Coma, Antoni Gual, Corinne Zara, Anna Lligoña · 2019 · European Addiction Research
  92. Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey
    Fausto Roila, Enzo Ballatori, Roberto Labianca, Filippo de Braud, Karen Borgonovo, Olga Martelli, Ciro Gallo, Angelo Tinazzi, Francesco Perrone · 2009 · Tumori Journal
  93. Off-Label Use of Rituximab in a Multipayer Insurance System
    Eliezer M. Van Allen, Todd Miyake, Nathan Gunn, Caroline M. Behler, Jeff Kohlwes · 2011 · Journal of Oncology Practice
  94. Regulating Ambiguous Risks: The Less than Rational Regulation of Pharmaceuticals
    W. Kip Viscusi, Richard Zeckhauser · 2015 · The Journal of Legal Studies
  95. Formulary systems and pharmacy and therapeutics committees in the Western Pacific Region: Exploring two Basel Statements
    Jonathan H-D Penm, Betty Bouad Chaar, Jiang Dechun, Rebekah Jane Moles · 2013 · American Journal of Health-System Pharmacy
  96. Informed Consent for Off-Label Use of Prescription Medications
    Zain Mithani · 2012 · The AMA Journal of Ethic
  97. New Uses for Older Drugs: The Tales of Aspirin, Thalidomide, and Gabapentin
    Joseph I Sirven · 2010 · Mayo Clinic Proceedings
  98. Gabapentin controlled substance status
    Levi S. Campbell, Tiffany N. Coomer, George K. Jacob, Ranee J. Lenz · 2021 · Journal of the American Pharmacists Association
  99. Enhancing Prescription Drug Innovation and Adoption
    G. Caleb Alexander, Alec O'connor, Randall Scott Stafford · 2011 · Annals of Internal Medicine
  100. Association of State-Imposed Restrictions on Gabapentin with Changes in Prescribing in Medicare
    Jordan S. Grauer, John D. Cramer · 2022 · Journal of General Internal Medicine